AK 1830
Alternative Names: AK-1830; ARRY-954Latest Information Update: 23 Apr 2024
At a glance
- Originator Array BioPharma
- Developer Array BioPharma; Asahi Kasei
- Class Analgesics; Anti-inflammatories; Small molecules
- Mechanism of Action TrkA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Back pain; Osteoarthritis
- Phase I Inflammation
Most Recent Events
- 31 Jan 2022 Asahi Kasei Pharma Corp completes a phase II trial in Back pain in Japan (PO) (JapicCTI205448)
- 28 Jul 2021 No recent reports of development identified for phase-I development in Inflammation in USA
- 26 Sep 2020 Asahi Kasei Pharma Corp completes enrollment in a phase II trial in low Back pain in Japan (JapicCTI-205448)